Recent Updates
Recently added Catalysts
RGEN Positive Sentiment

Repligen to Report Third Quarter 2025 Financial Results

Key Takeaway: Repligen Corporation will announce its third quarter 2025 financial results on October 28, 2025. A press release will precede the market opening, followed by a conference call at 8:30 a.m. ET to discuss the results. The call will be accessible to both domestic and international callers, and a webcast will also be available.
Price reaction · baseline $148.4 (2025-10-14 close) · hit pre-market · clean, no other RGEN news in the window
day 0 close · peak
+0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Repligen is set to report financial results, indicating ongoing business activity.
  • The company continues to engage with investors through a conference call.
  • Repligen's focus on innovative bioprocessing technologies shows growth potential.

Full Press Release Details

WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2025 financial results on Tuesday, October 28, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2025.
The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via theInvestor Relationssection of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. You can access the replay on theInvestor Relationssection of Company’s website.
About Repligen CorporationRepligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are“inspiring advances in bioprocessing”for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website atwww.repligen.com, and follow us onLinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Repligen Contact:Jacob JohnsonVP, Investor Relations(781) 419-0204investors@repligen.com

Frequently Asked Questions

When will Repligen report its Q3 2025 financial results?

Repligen will report its Q3 2025 financial results on October 28, 2025.

What time is the Repligen conference call?

The conference call will take place at 8:30 a.m. ET.

How can I access the Repligen conference call?

The call can be accessed by dialing toll-free (800) 715-9871 or (646) 307-1963.

Will the conference call be available later?

Yes, both the conference call and webcast will be archived for later access.

Last updated: Oct 15, 2025